Aura Biosciences, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Aura Biosciences, Inc. (AURA) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$79.32 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-11
- Aura Biosciences, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$45.64M.
- Aura Biosciences, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$33.69M.
- Aura Biosciences, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$25.56M.
- Aura Biosciences, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$26.13M.
- Aura Biosciences, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$106.19M.
- Aura Biosciences, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$86.92M.
- Aura Biosciences, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$76.41M.
- Aura Biosciences, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$58.76M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$45.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$79.32M 10-Q · filed 2026-08-11 | -$104.88M derived: sum of 3 quarters · filed 2026-08-11 | -$131.01M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$33.69M 10-Q · filed 2026-05-11 | -$59.24M derived: sum of 2 quarters · filed 2026-05-11 | -$85.37M derived: sum of 3 quarters · filed 2026-05-11 | -$112.39M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$25.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$51.69M derived: sum of 2 quarters · filed 2026-03-30 | -$78.71M derived: sum of 3 quarters · filed 2026-08-11 | -$106.19M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$26.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$53.15M derived: sum of 2 quarters · filed 2026-08-11 | -$80.63M 10-Q · filed 2025-11-13 | -$106.47M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$27.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$54.50M 10-Q · filed 2026-08-11 | -$80.34M derived: sum of 3 quarters · filed 2026-08-11 | -$101.38M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$27.48M 10-Q · filed 2026-05-11 | -$53.32M derived: sum of 2 quarters · filed 2026-05-11 | -$74.36M derived: sum of 3 quarters · filed 2026-05-11 | -$94.70M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$25.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$46.88M derived: sum of 2 quarters · filed 2026-03-30 | -$67.21M derived: sum of 3 quarters · filed 2026-03-30 | -$86.92M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$21.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$41.38M derived: sum of 2 quarters · filed 2025-11-13 | -$61.09M 10-Q · filed 2025-11-13 | -$83.22M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$20.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$40.04M 10-Q · filed 2025-08-13 | -$62.17M derived: sum of 3 quarters · filed 2025-08-13 | -$80.69M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$19.71M 10-Q · filed 2025-05-15 | -$41.84M derived: sum of 2 quarters · filed 2025-05-15 | -$60.35M derived: sum of 3 quarters · filed 2025-05-15 | -$78.65M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$22.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$40.64M derived: sum of 2 quarters · filed 2025-03-24 | -$58.94M derived: sum of 3 quarters · filed 2025-03-24 | -$76.41M 10-K · filed 2025-03-24 |
| 2023-09-30 | -$18.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$36.81M derived: sum of 2 quarters · filed 2024-11-12 | -$54.28M 10-Q · filed 2024-11-12 | -$70.84M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$18.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$35.77M 10-Q · filed 2024-08-08 | -$52.32M derived: sum of 3 quarters · filed 2024-08-08 | -$68.22M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$17.47M 10-Q · filed 2024-05-09 | -$34.02M derived: sum of 2 quarters · filed 2024-05-09 | -$49.93M derived: sum of 3 quarters · filed 2024-05-09 | -$63.39M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$16.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$32.46M derived: sum of 2 quarters · filed 2024-03-27 | -$45.93M derived: sum of 3 quarters · filed 2024-03-27 | -$58.76M 10-K · filed 2024-03-27 |
| 2022-09-30 | -$15.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$29.37M derived: sum of 2 quarters · filed 2023-11-09 | -$42.20M 10-Q · filed 2023-11-09 | -$53.84M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$13.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$26.30M 10-Q · filed 2023-08-09 | -$37.94M derived: sum of 3 quarters · filed 2023-08-09 | -$46.77M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$12.84M 10-Q · filed 2023-05-11 | -$24.47M derived: sum of 2 quarters · filed 2023-05-11 | -$33.31M derived: sum of 3 quarters · filed 2023-05-11 | -$42.16M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$11.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$20.47M derived: sum of 2 quarters · filed 2023-03-15 | -$29.32M derived: sum of 3 quarters · filed 2023-03-15 | -$35.25M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$8.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$17.69M derived: sum of 2 quarters · filed 2022-11-10 | -$23.62M 10-Q · filed 2022-11-10 | -$28.52M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$8.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$14.78M 10-Q · filed 2022-08-11 | -$19.69M derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$5.93M 10-Q · filed 2022-05-12 | -$10.83M derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$4.91M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | -$22.21M 10-K · filed 2022-03-23 | ||
| 2020-09-30 | -$17.30M 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |